Allogene Therapeutics

A clinical-stage biotechnology company developing allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease. Guidelines

[Allogene Therapeutics @AllogeneTx]

1 in 3 #LBCL patients will see their cancer return after 1L treatment. Discover how the ALPHA3 trial design combines investigational minimal residual disease (MRD) testing technology and an off-the-shelf #CART product to intervene early and potentially improve cure rates. $ALLO

Learn More About ALPHA3: https://t.co/pYNVYhm6tO

[Allogene Therapeutics @AllogeneTx]

Tomorrow, Allogene will be at the @Jefferies Global Healthcare Conference to share updates on our pipeline and progress in delivering #allogeneic #CART products at scale. Details can be found on the Investors section of our website. $ALLO #celltherapy

Learn More: https://t.co/GII3caBxhJ

[Allogene Therapeutics @AllogeneTx]

Important discussion from @TargetedOnc and @jeff_sharman on early ALPHA3 safety observations and investigational cema-cel’s potential in community outpatient settings for MRD-positive #LBCL. #allogeneic #CART $ALLO

[Targeted Oncology @TargetedOnc]

Phase 2 ALPHA3 shows cema-cel in MRD-positive large B-cell #lymphoma has no CRS/ICANS so far, enabling outpatient consolidation with manageable adverse effects. 🔬

🎥 Watch part 2 of the interview here: https://t.co/cvdKvsHeBC

#HemeOnc #DLBCL | @jeff_sharman @SarahCannonDocs

[Allogene Therapeutics @AllogeneTx]

Thank you @TargetedOnc and @jeff_sharman for advancing the conversation on MRD-guided intervention and the potential of #allogeneic #CART as consolidation in high-risk #LBCL. $ALLO

[Targeted Oncology @TargetedOnc]

🎥 WATCH: Jeff Sharman, MD (@SarahCannonDocs) discusses details & interim futility data from ALPHA3, showing allogeneic CAR T cema-cel clears MRD in high-risk #DLBCL as consolidation.

Part 1 of the interview here: https://t.co/wUYwhqe8DI

#Lymphoma #CARTTherapy | @jeff_sharman

[Allogene Therapeutics @AllogeneTx]

Allogene will participate in the @Jefferies Global Healthcare Conference in New York, sharing an update on our investigational pipeline and corporate strategy. Webcast details are available in the Investors section of our website. $ALLO #CART #celltherapy #allogeneic

Learn More: https://t.co/GII3caBxhJ

[Allogene Therapeutics @AllogeneTx]

At Allogene, we’re advancing #CAR T therapy to transform lives. Through bold innovation in #celltherapy, we’re working to expand access and redefine what’s possible for patients. Follow us to learn more. #allogeneic $ALLO

Learn More: https://t.co/PLxwgrbVAV

[Allogene Therapeutics @AllogeneTx]

Looking forward to participating in the upcoming TD Cowen 7th Annual Oncology Innovation Summit, where our leadership will share updates on our pipeline and corporate strategy. Visit the Investors section of our website for webcast details. $ALLO #CART #celltherapy #biotech

Learn More: https://t.co/GII3caBxhJ

[Allogene Therapeutics @AllogeneTx]

Experience the #allogeneic advantage. Our investigational AlloCAR T products aim to redefine the #CART landscape by addressing key limitations of autologous treatments – offering the potential for greater speed, scalability, and access for patients. #celltherapy $ALLO

Discover the Allogeneic Advantage: https://t.co/3DEWU4qNKd

[Allogene Therapeutics @AllogeneTx]

Missed it the first time? Our EVP of R&D and CMO, Dr. Zachary Roberts, sat down with @JohnCendpts for the @endpts R&D 15 to talk about the ALPHA3 trial and the potential of #allogeneic #CAR T to transform care for patients with #LBCL. $ALLO

Catch the Full Session on Demand: https://t.co/MAnKvn6xD5

[Allogene Therapeutics @AllogeneTx]

We’re proud to support LABEST 2026 this week, hosted by @UCLA. LABEST brings together the greatest minds in Los Angeles’ bioscience ecosystem. We look forward to connecting with our colleagues in cell therapy and beyond. #LABEST #biotech #celltherapy $ALLO

Learn More: https://t.co/cz3dbrajhV

[Allogene Therapeutics @AllogeneTx]

We aim to redefine #autoimmune disease treatment with ALLO-329, an investigational allogeneic #CART powered by Dagger® technology, which is designed to reduce or eliminate lymphodepletion. #celltherapy #allogeneic $ALLO

Uncover the Potential of ALLO-329: https://t.co/JxNyUlVIwG

[Allogene Therapeutics @AllogeneTx]

We are pleased to report our Q1 corporate update and business highlights. #allogeneic #CART #celltherapy $ALLO

View Our Q1 Update: https://t.co/ckfllxQqjr

[Allogene Therapeutics @AllogeneTx]

Allogene is advancing ALLO-329 – an investigational “off-the-shelf” AlloCAR T product for #autoimmune disease, powered by our proprietary Dagger® technology. See how we’re aiming to reset the immune system, expand access and transform care. #CART #celltherapy #allogeneic $ALLO

Uncover the Potential of ALLO-329: https://t.co/FRMq8VtPCF

[Targeted Oncology @TargetedOnc]

The ongoing ALPHA3 trial evaluating off-the-shelf CAR T cema-cel in #DLBCL may have major implications for community practices.

💬 Read more in this interview with Dr Jeff Sharman (@SarahCannonDocs at Willamette Valley Cancer Institute): https://t.co/Oj8vx5v8DJ | @jeff_sharman

[Allogene Therapeutics @AllogeneTx]

We’re proud to see our Executive Chairman and Co-Founder, @Arie_Belldegrun, MD, recognized in the Los Angeles Business Journal’s 2026 LA500, highlighting the most influential leaders in Los Angeles. Congratulations, Arie!

Learn More: https://t.co/7QSG1s2ujh

[Allogene Therapeutics @AllogeneTx]

For CAR T products, one size does not fit all. Our #ASGCT26 poster presentation highlights why cytokine engineering strategies must be customized to each CAR construct. These insights may help guide the design of future #allogeneic #CART platforms. $ALLO

Learn More: https://t.co/Lb7yZBiWqy

[Allogene Therapeutics @AllogeneTx]

A new 1L consolidation approach is being studied to help predict and potentially prevent relapse in #LBCL patients following frontline therapy. Learn more about the ALPHA3 clinical trial and its potential to revolutionize patient care. #CART #celltherapy #allogeneic $ALLO

Learn More About ALPHA3: https://t.co/pYNVYhm6tO

[Allogene Therapeutics @AllogeneTx]

Great event - thanks to @BenBeneski for joining the discussion and to @CancerResrch for including us. #FriendsCGT26 #allogeneic #celltherapy $ALLO

[John Connolly @John_E_Connolly]

Honored to moderate a fantastic panel on a key bottleneck in #celltherapy @parkerici @US_FDA @AllogeneTx @AstraZeneca @IovanceBio

[Allogene Therapeutics @AllogeneTx]

Join us for our Q1 2026 conference call on Wednesday, May 13 at 2:00 p.m. PT/5:00 p.m. ET. #CART #celltherapy $ALLO

Learn More: https://t.co/fjmOV1sRYv

[Allogene Therapeutics @AllogeneTx]

1 in 3 #LBCL patients will see their cancer return after 1L treatment. Discover how the ALPHA3 trial design combines investigational minimal residual disease (MRD) testing technology and an “off-the-shelf” #CART product to intervene early and potentially improve cure rates. $ALLO

Learn More About ALPHA3: https://t.co/pYNVYhm6tO